Overview of the VEXAS Syndrome
A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.
Read ArticleMost Popular
GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” framework has now reached psoriatic arthritis (PsA).
Read Article
Imaging in Axial Spondyloarthritis
The diagnosis of axial spondyloarthritis (axSpA) is clinical, however, there are still unmet needs, particularly in the diagnosis of early disease and evaluation of disease activity and progression.
Read Article
HLA-B27 Testing in Practice
A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along w
Manifestations and Treatment in Relapsing Polychondritis
A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease.
ICYMI: Consensus Against Interventional Injections for Chronic Spinal Pain
This article was originally published March 31, 2025, and is being shared again this week as part of our In Case You Missed It series. Enjoy!
What we need in very early arthritis
It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible.
Read Article
ICYMI: EGPA in 2025
This article was originally published February 13, 2025, and is being shared again this week as part of our In Case You Missed It series. Enjoy!
Read Article
ICYMI: ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain
This article was originally published April 7, 2025, and is being shared again this week as part of our In Case You Missed It series.
Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients
More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of disease-modifying anti-rheumatic drugs (DMARDs) use.
Read Article
A Review of Intracranial GCA
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.
Hmmm Really? (7.11.2025)
Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?
Read Article
Zasocitinib (Tyk2 Inhibitor) Efficacy in Psoriatic Arthritis
A highly selective, tyrosine kinase 2 inhibitor zasocitinib (TAK-279), was studied in a phase 2b trial and found to be effective and safe patients with active psoriatic arthritis (PsA).
Early DMARD Initiation Benefits in Psoriatic Arthritis
Mease et al has published the results of a cohort study showing early initiation of disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis (PsA) resulted in better outcomes compared to late initiation.
ICYMI: Axial Involvement in Psoriatic Arthritis
This article was originally published March 17, 2025, and is being shared again this week as part of our In Case You Missed It series. Enjoy!
Reducing Progression of Psoriasis to Psoriatic Arthritis
MedPage Today
Key Takeaways
- Psoriasis frequently progresses to PsA, and it has been uncertain whether drugs targeting TNF can delay or prevent it.
- This retrospective analysis examined progression rates in patients with severe psoriasis treated with TNF inhibitors versus phototherapy,
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
No Increased Malignancy Risk with Ixekizumab
A pooled analysis of 25 randomized clinical trials affirms the safety of ixekizumab (IXE) when used to treat patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).
Read Article
Immunomodulators in the Treatment of Autoimmune Hepatitis
EurekAlert!
Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease driven by autoimmune mechanisms, characterized by elevated serum aminotransferases, hypergammaglobulinemia, and interface hepatitis on histology.
Read Article
Interstitial Lung Disease and Lung Cancer Risk
A large prospective cohort study found that interstitial lung disease (ILD) is associated with an increased risk of lung cancer.
Read Article
